SLC5A2 and Hyperkalemia: In the CONFIDENCE trial, researchers are investigating whether the combination of finerenone and the SGLT2 inhibitor empagliflozin is superior to either drug alone, in reducing the degree of albuminuria and the risk of hyperkalemia (NCT05254002) [55].